VeriTeQ Rebrands its “Q Inside SmartMarker” to Lead its Radiation Dosimetry Business; Q Inside Smart Marker is World’s ...
March 27 2014 - 8:30AM
Business Wire
VeriTeQ’s radiation dosimetry products already
have six FDA clearances and CE approvals
VeriTeQ Corporation (“VeriTeQ” or “Company”) (OTC Markets:
VTEQ), a provider of implantable medical device identification and
radiation dose measurement technologies, announced today that it is
rebranding its Q Inside SmartMarker to lead its radiation dosimetry
business. Q Inside SmartMarker (previously known as DVS
SmartMarker®) is the only FDA- cleared implantable radio frequency
(“RF”) radiation sensor that provides localization of a tumor and
measures radiation dose at the tumor site. VeriTeQ’s radiation
dosimetry products have six FDA clearances and CE approvals, and
the Company has over 100 patents, patents pending, and exclusive
licenses.
Q Inside SmartMarker is an FDA-cleared, implantable radiation
sensor for use in breast and prostate cancer patients undergoing
photon external beam treatments. It is implanted in, or adjacent
to, solid-mass tumors and gathers data on the actual dose of
radiation being delivered to the tumor and surrounding normal
tissue. Q Inside SmartMarker is intended to be used in the
balancing between delivering maximum dose to the tumor while
minimizing the impact to healthy tissue. The sensor can confirm the
treatment is conforming to the physician’s plan, as even a small
deviation from planned dose can have a significant impact on
patient survival rates.
Scott R. Silverman, Chairman and CEO of VeriTeQ, stated,
“Radiation under-dosing and, perhaps more importantly, radiation
overdosing have been a top concern of the medical community for
years. Confirming the delivered dose of radiation is known to have
a direct and significant impact on treatment efficacy and patient
survival rates, and our Q Inside SmartMarker can support healthcare
providers with this potentially life-saving data.”
According to the ECRI Institute, radiation or CT overdose make
the list of the Top 10 Technology Hazards each year going back at
least eight years. These hazards include radiation overdose and
other errors during radiation therapy; unnecessary exposures and
radiation burns from diagnostic radiology procedures; and exposure
hazards from radiation therapy and CT.
Q Inside SmartMarker is compatible with a large variety of
commercially available systems including, but not limited to,
CyberKnife System, Varian kV Trilogy System, TomoTherapy, Siemens
MV CBCT, and Resonant Medical.
About VeriTeQ
VeriTeQ develops innovative, proprietary RFID technologies for
implantable medical device identification, and dosimeter
technologies for use in radiation therapy treatment. VeriTeQ offers
the world's first FDA cleared RFID microchip technology that can be
used to identify implantable medical devices, in vivo, on demand,
at the point of care. VeriTeQ's dosimeters provide patient safety
mechanisms while measuring and recording the dose of radiation
delivered to a patient in real time. For more information on
VeriTeQ, please visit www.veriteqcorp.com.
Statements in this press release about our future expectations,
including that the Company’s Q Inside SmartMarker will lead its
radiation dosimetry business, constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934, and as
that term is defined in the Private Litigation Reform Act of 1995.
Such forward-looking statements involve risks and uncertainties and
are subject to change at any time, and our actual results could
differ materially from expected results. These risks and
uncertainties include, without limitation, VeriTeQ’s ability to
raise capital; as well as other risks. Additional information about
these and other factors may be described in VeriTeQ’s Forms 10-Q,
filed on August 9, 2013 and November 14, 2013, and future filings
with the Securities and Exchange Commission The Company undertakes
no obligation to update or release any revisions to these
forward-looking statements to reflect events or circumstances after
the date of this statement or to reflect the occurrence of
unanticipated events, except as required by law.
VeriTeQAllison Tomek,
561-846-7003atomek@veriteqcorp.comorRedChip CompaniesBrendan
Hopkins, 1-800-RED-CHIP (733-2447) Ext 134Bhopkins@redchip.com
VeriTeQ (CE) (USOTC:VTEQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
VeriTeQ (CE) (USOTC:VTEQ)
Historical Stock Chart
From Apr 2023 to Apr 2024